The inward rectifier potassium (Kir) channel Kir4.1 plays essential roles in modulation of neurotransmission and renal sodium transport and may represent a novel drug target for temporal lobe epilepsy and hypertension. The molecular pharmacology of Kir4.1 is limited to neurological drugs, such as fluoxetine (Prozac ª ), exhibiting weak and nonspecific activity toward the channel. The development of potent and selective small-molecule probes would provide critically needed tools for exploring the integrative physiology and therapeutic potential of Kir4.1. A fluorescence-based thallium (Tl + ) flux assay that utilizes a tetracycline-inducible T-Rex-HEK293-Kir4.1 cell line to enable high-throughput screening (HTS) of small-molecule libraries was developed. The assay is dimethyl sulfoxide tolerant and exhibits robust screening statistics (Z 0 = 0.75 -0.06). A pilot screen of 3,655 small molecules and lipids revealed 16 Kir4.1 inhibitors (0.4% hit rate). 3,3-Diphenyl-N-(1-phenylethyl)propan-1-amine, termed VU717, inhibits Kir4.1-mediated thallium flux with an IC 50 of *6 lM. An automated patch clamp assay using the IonFlux HT workbench was developed to facilitate compound characterization. Leak-subtracted ensemble ''loose patch'' recordings revealed robust tetracycline-inducible and Kir4.1 currents that were inhibited by fluoxetine (IC 50 = 10 lM), VU717 (IC 50 = 6 lM), and structurally related calcium channel blocker prenylamine (IC 50 = 6 lM). Finally, we demonstrate that VU717 inhibits Kir4.1 channel activity in cultured rat astrocytes, providing proof-of-concept that the Tl + flux and IonFlux HT assays can enable the discovery of antagonists that are active against native Kir4.1 channels.
INTRODUCTION

I
nward rectifier potassium (Kir) channels are broadly expressed in excitable and nonexcitable tissues where they regulate numerous physiological processes, including nerve and muscle cell excitability, hormone secretion, and epithelial ion transport. 1 The Kir channel superfamily is comprised of 16 known genes (KCNJx) in humans, which are separated into seven subgroups (Kir1.x-Kir7.x) based on amino acid identity. Kir4.1 (KCNJ10) is expressed predominantly in brain and spinal cord astrocytes, retinal Muller glia, stria vascularis and glia of the inner ear, and renal tubule epithelial cells. Consistent with its localization, targeted deletion of KCNJ10 in mice produces severe motor impairment, deafness, and premature death. [2] [3] [4] [5] [6] The recent discovery 7, 8 of loss-of-function mutations in KCNJ10 in patients with SeSAME (seizures, sensorineural deafness, ataxia, mental impairment, electrolyte imbalance) or EAST (epilepsy, ataxia, sensorineural deafness, salt-wasting tubulopathy) syndrome confirmed that Kir4.1 plays important roles in humans and may represent a druggable target for epilepsy and hypertension. Kir4.1 constitutes the major K + conductance in brain and spinal cord astrocytes and contributes to a large negative membrane potential in these cells. It is generally believed that K + released into the (DCT). In the DCT, NaCl absorption is mediated by the thiazide diuretic-sensitive NaCl cotransporter (NCC), which is located in the apical membrane of this nephron segment. Heteromeric Kir4.1/5.1 channels expressed in the basolateral membrane of the DCT (1) recycle K + across the basolateral membrane to help maintain the activity of the Na + -K + -ATPase, and (2) hyperpolarize the basolateral membrane potential to facilitate the electrogenic exit of Cl -ions.
Knockout of KCNJ10 in mice recapitulates the salt-wasting phenotype of subjects with SeSAME/EAST syndrome. 8 However, deletion of the Kir5.1-encoding gene KCNJ16 paradoxically increases renal NaCl reabsorption. 9 As alluded to earlier, unlike homomeric Kir4.1 channels, Kir4.1/5.1 is critically regulated by intracellular pH (pHi) and is partially inhibited at physiological pHi. A loss of this negative regulation in KCNJ16-knockout mouse leads to an increase in Kir4.1 activity and NaCl reabsorption in the DCT. 7 Kir4.1/5.1 antagonists would be expected to mimic thiazide diuretics by indirectly inhibiting NCC-mediated NaCl reabsorption. However, they could offer some important advantages over conventional diuretics due to the localization of the channel on the basolateral membrane. [10] [11] [12] Loop and thiazide diuretics must first be secreted by renal proximal tubule cells before reaching their sites of action on the apical membrane. [13] [14] [15] [16] Interactions between diuretics and other secreted drugs, including antibiotics, NSAIDs, antivirals, as well as organic acid in the setting of renal failure, can limit their secretion and natriuretic effects. Kir4.1/5.1 inhibitors that act directly on the basolateral membrane should circumvent this limitation. Furthermore, Zaika et al. (2013) reported recently that dopamine inhibits Na + reabsorption in the cortical collecting duct (CCD) through inhibition of Kir4.1 homomeric and Kir4.1/5.1 heteromeric channels. 17 Conceivably, Kir4.1/5.1
antagonists would exhibit greater clinical efficacy than thiazide diuretics due to inhibition of sodium reabsorption in multiple nephron segments, unlike conventional diuretics that tend to work on single segments. Identifying subtype-selective modulators active against Kir4.1 or Kir4.1/5.1 channels will be essential for investigating the druggability of Kir4.1 as an antihypertensive target. Loss-of-function mutations in the methyl CpG binding protein 2 (MECP2) gene give rise to Rett syndrome, a neurological disorder characterized by difficulties with communication, learning, and motor coordination. Of relevance to the present discussion, the MECP2-null mouse exhibits increased expression of Kir4.1 in the locus coeruleus, a brainstem region involved in regulation of respiratory activity by carbon dioxide (CO 2 ). 18 Zhang et al. (2011) proposed that an increase in CO 2 /pH-insensitive Kir4.1 homotetrameric channels and loss of CO 2 /pH-sensitive Kir4.1/5.1 heteromeric channels lead to a blunted respiratory response to CO 2 and dysregulation of respiratory rhythmogenesis in Rett syndrome patients. If this is correct, and barring untoward general effects on neurotransmission, then small-molecule antagonists of homotetrameric Kir4.1 channels may help correct breathing abnormalities in Rett syndrome patients. 19, 20 Evaluating the therapeutic potential and of Kir4.1 awaits the development of potent, specific, and bioavailable small-molecule modulators, as the molecular pharmacology of Kir4.1 is limited to a small number of neurological drugs (e.g., selective serotonin reuptake inhibitors and tricyclic antidepressants) exhibiting weak offtarget activity toward the channel. Here we report the development and validation of a fluorescence-based thallium (Tl + ) flux assay to enable high-throughput library screening and an automated patch clamp electrophysiology assay that utilize an IonFlux HT workstation to facilitate hit validation and characterization.
MATERIALS AND METHODS
Molecular Biology and Stable Cell Line Generation
The human Kir4.1 channel open-reading frame was purchased from OriGene Technologies (NM_002241.4; Origene) and subcloned into pcDNA5/TO (Life Technologies) using standard molecular biology techniques. Polyclonal T-REx-HEK293 cell lines stably transfected with pcDNA5/TO-Kir4.1 were established essentially as described previously. 21, 22 Monoclonal cell lines were isolated through limiting dilution in 384-well plates and tested for tetracycline inducible Tl + flux, as outlined below (see Tl + Flux Assay Development and Library Screening). The cell lines were maintained in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal bovine serum (FBS), 50 U/mL penicillin, 50 mg/mL streptomycin, 5 mg/mL blasticidin S, and 250 mg/mL hygromycin in a 5% CO 2 incubator at 37°C.
Manual Patch Clamp Electrophysiology
T-REx-HEK293-Kir4.1 cells were used for patch clamp analysis following overnight induction with tetracycline (1 mg/mL). The standard pipette solution contained (in mM) 135 KCl, 2 MgCl 2 , 1 EGTA, 10 HEPES-free acid, and 2 Na 2 ATP (Roche), pH 7.2, 275 mOsmol/kg. The standard bath solution contained (in mM) 135 NaCl, 5 KCl, 2 CaCl 2 , 1 MgCl 2 , 5 glucose, and 10 HEPES-free acid, pH 7.4, 290 mOsmol/kg. Electrodes pulled from capillary glass had resistances of 3.0-3.5 MO when filled with pipette solution. Voltage and current signals were generated and acquired using an Axopatch 200B amplifier and Digidata 1322A analog-to-digital converter (Molecular Devices). Data acquisition and analysis were performed using pClamp 9.2 software (Molecular Devices). All recordings were made at room temperature (20°C-23°C).
Western Blot Analysis
Monoclonal T-REx-HEK293-Kir4.1 cells were plated at a density of 1 · 10 5 cells/cm 2 and cultured overnight in the absence or presence of tetracycline (0.01-1.0 mg/mL), washed three times with ice-cold phosphate-buffered saline (PBS), and solubilized in ice-cold RIPA buffer containing (in mM) 150 NaCl, 100 NaF, 50 Tris-HCl (pH 8.0), 35 sodium deoxycholate, 5 EDTA, 1% Triton X-100, 0.1% SDS, and 1 · protease inhibitor cocktail. Cell lysates were scraped into Eppendorf tubes, sonicated, rotated end-over-end for 30 min at 4°C, and then centrifuged for 10 min to pellet insoluble material. The protein concentration of cleared lysates was quantitated using BCA reagent (Thermo Scientific). Cell lysates were either used immediately or frozen as single-use aliquots at -80°C for subsequent immunoblot analysis. Proteins were separated electrophoretically using 10% Bis-Tris NuPAGE gels (Life Technologies) and transferred to 0.45-mm-pore nitrocellulose membranes (BioRad) for immunoblot analysis. Membranes were blocked overnight at 4°C in Tris-buffered saline (25 mM Tris, 1.3 mM KCl, and 137 mM NaCl) containing 0.1% TWEEN-20 (TBST) and 5% nonfat milk. Membranes were incubated for 1 h at room temperature in polyclonal Kir4.1 antiserum (Alomone Labs) diluted 1:500 in milk-TBST and subsequently for 1 h at room temperature in milk-TBST containing HRP-conjugated secondary antiserum diluted 1:40,000. Protein bands were visualized on film using enhanced chemiluminescence detection methods (Thermo Scientific). Membranes were stripped in buffer containing 100 mM 2-mercaptoethanol, 62.5 mM Tris-HCl (pH 6.7), and 2% SDS (50°C for 30 min) and reprobed with b-actin antiserum. 
Tl
Concentration-Response Curves
Compound master plates were created by serially diluting compounds 1:3 from 10 mM stock in 100% DMSO using the BRAVO liquid handler (Agilent Technologies). Assay daughter plates were created using the ECHO 555 liquid handler (Labcyte), transferring 240 nL from the master plate to the daughter plate for each well followed by addition of 40 mL of AB resulting in antagonist compound concentration-response curves (CRCs) starting at 60 mM (2· final concentration). Concentrationresponse series were done in triplicate in the daughter plate. Cell plates and daughter compound plates were loaded onto an FDSS 6000. Baseline readings were taken (10 images at 1 Hz; excitation, 470 -20 nm; emission, 540 -30 nm) and 20 mL of test compounds was added followed by 50 images at 1 Hz additional baseline. Following a 20-min incubation period, baseline readings were taken for 30 s followed by addition of Tl + stimulus buffer, followed by a 4-min read.
Data were analyzed using Excel (Microsoft Corp.). Raw data were opened in Excel and each data point in a given trace was divided by the first data point from that trace (static ratio). For experiments in which antagonists were added, data were again normalized by dividing each point by the fluorescence value immediately before the thallium addition to correct for any subtle differences in the baseline traces after the compound incubation period. The slope of the Step Notes 1. Plate induced/uninduced cells in 384-well assay plates with multichannel pipettor (Biohit). 2. Assay buffer with 0.5 mg/mL stock concentration of Fluozin-2 and 20% weight per volume Pluronic F-127 added with multidrop combi reagent dispenser (Thermo Scientific). 3. Plates lidded and maintained at room temperature. 4. Excess dye was removed with ELx405 microplate washer (BioTek) and replaced with assay buffer. 5. Columns 1-2 and 23-24, assay buffer -fluoxetine or DMSO added with multichannel pipettor in checkerboard pattern. 6. FDSS-integrated 384-channel pipettor (Hamamatsu) dispenses compounds in all wells in columns 3-23. 7. Plates maintained at room temperature. 8. FDSS-integrated 384-channel pipettor dispenses thallium stimulus in all wells. 9. Reading at 1 Hz exposure, baseline read for 10 s, 4-min total sampling time.
fluorescence increase that begins 5 s after Tl + addition and ends 15 s after Tl + addition was calculated. The data were then plotted in
Origin software (OriginLab Software, Inc.) to generate CRCs after correcting for the slope values determined for baseline waveforms generated in the presence of vehicle controls. Potencies were calculated from fits using a four-parameter logistic equation.
Automated Patch Clamp Electrophysiology
T-REx-HEK293-Kir4.1 cultured cells were induced overnight with 0.1 mg/mL tetracycline prior to IonFlux automated electrophysiology. For cell isolation, cultured cells were washed with Ca-and Mgfree HBSS buffer, followed by DetachinÔ solution (Genlantis) to detach them. The cells were resuspended in extracellular solution at 3 · 10 6 cells/mL. The extracellular solution contained 135 mM NaCl, ' ' such that the current measured is the sum of all 20 cells of the ensemble. Given the variability in the quality of the seal for each given cell, the ensemble recording ends up being similar to ''loose seal'' recording conditions. For recording Kir4.1 current, cells were voltage clamped at -80 mV (which is near E K for the solution pair used), stepped to -120 mV and then ramped at 0.5 mV/s to +120 mV, and finally stepped back to -80 mV. Given that the cells are being held near E K , the current flow at the holding potential is primarily nonspecific leak current, due in large part to the ''loose seal'' recording conditions. Kir4.1-specific current was estimated using the following formula:
This equation is based on the assumption that the current measured at -80 mV is exclusively nonspecific leak. Data analysis and graphical presentation were performed using a combination of IonFlux, Excel, and Origin software.
Animals
Experiments were performed on Sprague-Dawley rats and were approved by the University of Alabama Institutional Animal Care and Use Committee.
Astrocyte Cultures
Spinal cord astrocytes were cultured in phenol red-free medium as described previously. 5 Briefly, postnatal day 0 (P 0 ) pups were decapitated and spinal cords were dissected into ice-cold serum-free Eagle's minimum essential medium (EMEM) (Gibco) containing 20 mM glucose. Once the meninges were stripped, the cords were minced and placed into an O 2 -saturated papain solution (Worthington) for 20 min. The tissue was washed twice with spinal cord astrocyte media (EMEM supplemented with 10% fetal calf serum, 20 mM glucose, and penicillin/streptomycin) and then triturated. Cells were plated at a density of 1.0 · 10 6 cells/mL on polyornithine-and laminin-coated coverslips. The media were changed every day for the first 3 days and then every fourth day thereafter. Electrophysiology was performed on astrocytes that had been in culture for 7-10 days.
Astrocyte Electrophysiology
Whole-cell voltage-clamp recordings were made as described previously. 5 Coverslips were transferred to a Zeiss Observer D1 mi- 
RESULTS
Cell Line Characterization
A monoclonal T-REx-HEK293 cell line that expresses Kir4.1 from a tetracycline-inducible promoter was developed and characterized. Tetracycline-inducible cell lines are useful because (1) they can limit potential cell line degeneration and loss of assay performance due to K + channel overexpression, and (2) they provide a convenient internal control for distinguishing effects of pharmacologically active compounds on endogenous Tl + flux pathways versus the overexpressed Kir channel of interest. Manual whole-cell patch clamp electrophysiology was used to characterize the functional and pharmacological properties of Kir4.1 channels expressed in T-REx-HEK293 cells. Under current clamp conditions, the resting membrane potential of cells cultured overnight in the absence or presence of tetracycline (1 mg/mL) was -23.8 -3.9 mV (n = 8) and -72.5 -0.6 mV (n = 5), respectively. The cells were voltage clamped at -75 mV, and then stepped between -120 mV and +120 mV in 10-mV increments for 250 ms to evoke whole-cell currents. Uninduced cells exhibited relatively small-amplitude outward currents at positive test potentials (Fig. 1A) carried by voltage-gated K + and Cl -channels endogenously expressed in HEK293 cells. 26, 27 In sharp contrast, tetracycline induced the expression of large-amplitude inward and outward currents, exhibiting weak rectification at positive test potentials (Fig. 1B) . The current was inhibited by barium (not shown) as well as the selective serotonin reuptake inhibitor (SSRI) fluoxetine (Fig. 1C) , as reported by Kurachi and colleagues. 28, 29 The Figure 1D . Fluoxetine also inhibited the endogenous outward current in HEK cells (Fig. 1C, D) , consistent with reports that the drug inhibits other ion channels. [30] [31] [32] Thus, overnight induction with tetracycline gives rise to robust, fluoxetineinhibitable Kir4.1 channel activity in this stable cell line. As shown in Figure 1E , Western blot analysis revealed that overnight incubation with tetracycline led to the dose-dependent induction of Kir4.1 channel expression that reached a maximum level with 0.1 mg/mL tetracycline. No Kir4.1-immunoreactive bands were observed in lysates prepared from nontransfected ''parental'' T-REx cells, indicating that the antiserum is specific for Kir4.1. . Figure  2A and B shows FluoZin-2 fluorescence emission traces recorded from wells that contain uninduced or induced cells, respectively, before and after addition of various Tl + concentrations (arrow; see below). The Tl + -induced fluorescence increase in uninduced cells ( Fig. 2A) was relatively small, reflecting the movement of the cation through endogenous pathways. However, induction of Kir4.1 expression led to a dramatic increase in the rate and extent of Tl + flux (Fig. 2B) . Indeed, we were concerned that Tl + flux was so high that the indicator dye may become saturated and limit the assay's ability to detect weak inhibitors or agonists, and therefore we established a Tl + CRC to identify a submaximal concentration that still provided a robust signal window. The inset of Figure 2B shows that mean -SEM change in FluoZin-2 fluorescence exhibited a sigmoidal, dose-dependent relationship that saturated around 2 mM Tl + . The concentration required to evoke *80% of the maximal response was determined from the fit of a four-parameter logistic function to be 0.84 mM. This concentration was used for assay development and the pilot screen to provide ''headroom'' for identifying small-molecule activators of Kir4.1. The sensitivity of the assay to the small-molecule solvent DMSO was determined by assessing Tl + flux across a twofold dilution series of DMSO ranging from 0.1% to 5% v/v. As shown in Figure 2C , Tl + flux was unaffected at concentrations up to 0.3% v/v, but it dropped off dose dependently at higher concentrations. DMSO had no effect on Kir4.1-mediated Tl + flux at the screening concentrations of 0.1% and 0.3% v/v. ''Checkerboard'' assays were performed on 3 separate days to determine the well-to-well uniformity within a plate and day-to-day reproducibility. Every other well of a 384-well plate that contains tetracycline-induced T-REx-HEK-293-Kir4.1 cells was treated for 20 min with DMSO (vehicle) or 100 mM fluoxetine (nonspecific blocker) before initiating Tl + flux. In Figure 2D , Tl + -induced FluoZin-2 fluorescence from each well of one plate is plotted, with the mean fluorescence and three standard deviations from the mean indicated with a m and 3s, respectively. The assay conditions afforded clear separation of the two cell populations, yielding a mean -SEM Z 0 value for nine plates on 3 separate days of 0.75 -0.06. Thus, the assay is robust, reproducible, and suitable for HTS.
Tl
Discovery of a Novel Kir4.1 Inhibitor
The assay was validated with a screen of 3,655 small molecules and bioactive lipids at the Vanderbilt HTS center. Small molecules and lipids were tested at a nominal concentration of 10 mM (0.1% DMSO) and 3 mM (0.3% DMSO), respectively. The mean Z 0 for the entire 19-plate run, calculated from the peak fluorescence amplitude in vehicle or fluoxetinetreated wells, was 0.82 -0.04. The hit rate was 0.4% (16/3,655 compounds). All of the hits were inhibitors; none of which were lipids. The most potent inhibitor identified was 3,3-diphenyl-N-(1-phenylethyl) propan-1-amine, which we termed VU717. The chemical structure is shown in Figure 3A . In Tl + flux assays, VU717 dosedependently inhibited Kir4.1 activity with an IC 50 of 6.3 mM and Hill coefficient of 4.5 (Fig. 3B, C) .
Development of an Automated Patch Clamp Assay for Kir4.1 Using the IonFlux HT
Patch clamp electrophysiology is the gold standard technique for interrogating the pharmacology of ion channels. However, manual patch clamping is low-throughput and thus it imposes a considerable bottleneck. We therefore set out to develop an automated patch clamp assay to minimize this bottleneck and facilitate the development of Kir4.1 channel modulators.
We first established the time required to induce Kir4.1 channel expression and function in T-REx-HEK293-Kir4.1 cells following induction with tetracycline. Figure 4A 
KIR4.1 ASSAY DEVELOPMENT
We then assessed Kir4.1 channel activity in cells induced for the same time period using an IonFlux HT automated patch clamp workstation. The IonFlux HT utilizes a network of microfluidic channels that enables fully automated cell introduction, trapping, sealing, whole-cell formation, and voltage clamp using 64 independent voltage clamp amplifiers. Recordings are made in the ''loose patch'' configuration from an ensemble of 20 cells per channel. This approach has the advantage of increasing the robustness and throughput of recordings, but may suffer from significant ''leak'' current introduced by sub-Giga-Ohm-resistance seals. We therefore employed Ba 2 + to discriminate Kir4.1-mediated current from leak current. Cells were voltage clamped at a holding potential of -80 mV, which is near the calculated Nernst equilibrium potential for K + , and then the voltage was stepped to a test potential of -120 mV. Currents were leak subtracted as described in Materials and Methods. The mean -SEM of Ba 2 + -sensitive current at -120 mV is shown in Figure 4B . In contrast to the Western blot results that show abundant Kir4.1 protein expression after only 6 h of tetracycline induction, no Ba 2 + -sensitive currents were detectable at this time point. Following 18 h of induction, however, robust Ba 2 + -inhibitable currents were clearly observed. Cells were therefore induced overnight with tetracycline in all subsequent experiments. Figure 4C shows representative, leak-subtracted current traces recorded in the absence or presence of 300 mM Ba 2+ from cells subjected to a voltage ramp between -120 mV and +120 mV. In control solution, the current exhibited a steep voltage- dependent relationship between -120 mV and +50 mV, a plateau around +60 mV, and rectification at potentials more positive than +70 mV. This current waveform is similar to that recorded from T-REx-HEK293-Kir4.1 cells using the manual patch clamp technique (Fig. 1D ). The inward current was abolished by 300 mM Ba 2+ . Figure 5A summarizes the current amplitudes recorded in the absence or presence of Ba 2 + from an entire 384-well format plate on two separate days. Each plate consists of 32 ''experimental patterns,'' each containing 2 cell ''traps.'' Each data point represents the average current amplitude from two daughter traps. The mean -SD current amplitudes in control and Ba 2+ -treated cells were, respectively, -5857 -1438 and 886 -478 pA. Out of 64 patterns tested, 59 of these led to successful cell trapping, whole-cell formation, and recordings of Ba 2+ -inhibitable Kir4.1 channel activity (92% success rate).
The mean -SEM Ba 2+ CRC recorded on two separate days is shown in Figure 5B . The IC 50 values derived from 4-parameter logistic functions for days 1 and 2 were 3.59 -0.12 and 2.37 -0.12 mM, respectively. Taken together, these data indicate that robust Kir4.1-dependent channel activity can be readily measured using the IonFlux HT workstation ( Table 2) .
Characterization of Small-Molecule Kir4.1 Antagonists with the IonFlux HT VU717 and fluoxetine share some chemical features that likely contribute to their activity toward Kir4.1, including two hydrophobic benzene rings and an ionizable secondary amine group (Fig. 6A) .
In an effort to identify other inhibitors of Kir4.1, a search of the National Center for Biotechnology Information PubChem database for structurally related substances revealed that the calcium channel blocker prenylamine (3,3-diphenyl-N-(1-phenylpropan-2-yl)propan-1-amine) shares these chemical features (Fig. 6A) . Prenylamine was formerly used clinically as a vasodilator in the treatment of angina pectoris, but it was discontinued because of its propensity to induce torsades de pointes by blocking hERG channels. 35 The potencies of VU717, prenylamine, and fluoxetine were compared across a threefold dilution series ranging from 300 nM to 100 mM. The mean -SEM CRCs for the three compounds are shown in Figure 6B . The IC 50 values for VU717 (n = 6-43), prenylamine (n = 4-20), and fluoxetine (n = 2-17) were 6.0 -1.3, 6.2 -1.0, and 10.4 -3.2 mM, respectively, and the Hill coefficients were 1.9, 2.0, and 2.3, respectively. For comparison, CRCs were established in Kir4.1 Tl + flux assays for VU717, prenylamine, and fluoxetine, which yielded IC 50 values of 9.72 -2.0, 14.8 -1.9, and 22.8 -0.9 mM, respectively. Thus, although the potencies derived from electrophysiology and Tl + flux assays differ by *2.5-fold, the Tl + flux assay assigned the correct rank-order potency across this series.
VU717 Inhibits Native Kir4.1 Channels in Astrocytes
Given that VU717 was discovered in a screen against a heterologously expressed channel, we assessed the effects of the compound on astrocyte currents to determine whether VU717 is active against native Kir4.1 channels. Astrocytes that exhibit significant arborization were selected under DIC microscopy for voltage clamp recording (Fig. 7A, inset) . In response to a linear voltage ramp ( -160 mV to + 160 mV over 300 ms) these cells responded with a large amplitude current that reversed at -80 mV (Fig. 7B) . This current was nearly, completely inhibited in the presence of 250 mM Ba 2 + containing ACSF, identifying this current as Kir4.1-mediated current as previously described. 5, 36 Barium was then washed off and the currents quickly returned to baseline. ACSF that contains 10 mM or 30 mM VU717 was then applied to the voltage clamped cell until maximum inhibition was achieved. Figure 7B shows that 10-30 mM VU717 inhibited *90% of the whole-cell current at -120 mV, which is nearly identical to that blocked by 250 mM barium. This is comparable to that observed in conventional patch clamp recordings from Kir4.1-expressing HEK293 cells in which VU717 inhibited 94% -1.8% (n = 5) of current at -120 mV. This data clearly indicates that the Tl + flux assay is capable of identifying inhibitors of native Kir4.1 channels.
DISCUSSION
The assays developed herein should support a robust small-molecule probe discovery effort for Kir4. to the K + channel target, can be rapidly identified and triaged in screens against uninduced cells. As shown in Figure 2A and B, Kir4.1-mediated Tl + flux dominates the signal window, which increases the ability of the assay to identify specific Kir4.1 modulators.
In pilot experiments, we noted that the fluorescence emission of FluoZin-2 approached its asymptotic value within *60 s of adding Tl + to the cell plate. Such robust Tl + flux was not surprising given that (1) the cell line was selected for high Kir4.1 expression and function, and (2) Kir4.1 is a ''weak rectifier'' that exhibits a high openstate probability across a broad range of membrane potentials, unlike some voltage-gated K + channels that require depolarization for channel opening and Tl + flux. 37 However, the robustness of Tl + flux raised concerns that the dye would become saturated and fail to report subtle changes in Kir4.1 activity caused by pharmacologically weak modulators in a screen. We reasoned that using a lower Tl + concentration would prevent saturation, increase the sensitivity of the assay, and provide ''headroom'' for identifying activators. From dose-response experiments, an EC 80 concentration of 0.84 mM was determined, which represents only 15% of that used previously by our group. 22, 23, 34, 35 Despite the use of lower Tl + concentrations, which tended to slightly increase the well-to-well variability in fluorescence and reduce the mean Z 0 score (data not shown), the assay generated robust screening statistics, indicating that it is suitable for HTS of chemical libraries. Our studies of VU717 show that the assay is clearly capable of identifying a *6 mM IC 50 inhibitor of Kir4.1 in a primary screen, which is a reasonable starting point to developing a submicromolar inhibitor suitable for in vitro and ideally in vivo pharmacology.
With an anticipated hit rate of 0.4%, it would take several weeks to characterize a hit collection from a large compound screen using ''gold standard'' manual patch clamp electrophysiology techniques. We therefore evaluated the IonFlux HT as an automated patch clamp workstation for characterizing Kir4.1 modulators in a shorter time frame while maintaining fidelity. The IonFlux platform technology is based on the Fluxion's proprietary microfluidic system, which enables ensemble cell recording in a continuous manner. While already validated for the study of ligand-gated, voltage-gated, sodium, and hERG channel pharmacology, 24, 25 this is the first study to
show that the IonFlux platform can be adapted for the study of Kir channel pharmacology. Kir4.1 is considered a ''weak rectifier'' since a decrease in channel conductance (i.e., rectification) is only observed at relatively large positive potentials (e.g., Fig. 4A ). This presented a challenge for discriminating Kir4.1-derived current in ''loose patch'' recordings contaminated by ''leak'' current, because both channelmediated and leak currents exhibit Ohmic (linear) current-voltage relationships across most of the voltage range tested. To circumvent this problem, we reasoned that all of the Kir4.1-mediated current would reverse directions at the Nernst equilibrium potential for potassium (E K ), which was approximately -80 mV under the recording conditions used as opposed to 0 mV for leak-mediated currents. Leak current, defined as the offset current at -80 mV multiplied by 1.5 (i.e., -80 mV · 1.5 = -120 mV), was subtracted from the wholecell current amplitude at -120 mV to yield values for leak-subtracted Kir4.1 current amplitude. The results suggest that this platform is sufficiently robust ( > 90% success rate) to provide an initial electrophysiological characterization of small-molecule inhibitors of Kir4.1. With a runtime of *30 min per plate and the ability to characterize up to 30 compounds along with controls on a given plate, the system will be capable of producing CRCs for hundreds of compounds per day.
In conclusion, we have developed and validated a robust Tl + flux assay to support a primary screen for small-molecule modulators of Kir4.1. A pilot screen of 3,655 small molecules and lipids and a subsequent structural homology search led to the discovery of the novel Kir4.1 antagonists VU717 and prenylamine. In addition, we demonstrated for the first time that Kir4.1 channel pharmacology can be characterized in automated loose patch clamp electrophysiology assays using the IonFlux HT workstation. The development of smallmolecule Kir4.1 modulators using these assay platforms will provide critically needed tools for investigating the integrative physiology and therapeutic potential of Kir4.1 in temporal lobe epilepsy and hypertension. 
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